Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock

NCT03683329 | Completed Phase 3 DMC

• 1 other identifier: DéPOH-IPC 2015-022
• Study Type: interventional
• Target: 398
• Locations: 1 country
• Sites: 1

Brief Summary

De-escalation aims at reducing the use of broad-spectrum antibiotics and therefore the emergence of multidrug-resistant (MDR) pathogens. Observational studies suggested that this strategy seems to be safe. However, there is no adequate, direct evidence showing de-escalation of antimicrobial agents to be effective and safe for onco-hematology patients with sepsis or septic shock. Thus, randomized clinical trials are needed for testing the safety and efficiency of de-escalation of antimicrobial therapy. The investigator's hypothesis is that de-escalation of empirical antimicrobial therapy in onco-hematology patients with sepsis or septic shock is noninferior to the continuation of empirical antimicrobial therapy. The first aim of the study is to demonstrate that de-escalation is noninferior to the continuation of broad-spectrum antibiotics in terms of hospital mortality. The secondary aims are to compare the two strategies in terms of mortality, duration of antimicrobial therapy, durations of mechanical ventilation, vasopressor use, numbers of superinfections, organ failure. Antimicrobial de-escalation (ADE) of antimicrobial therapy is a strategy proposed to allow for the rational use of broad-spectrum antimicrobial therapy as the empiric treatment for infections and minimize the overall exposure to these broad-spectrum agents. The need for prompt, effective antimicrobial therapy for patients with known or suspected infections is widely accepted. This principle leads to the use of very broad-spectrum antimicrobial therapy to increase the odds that all suspected potential pathogens are adequately treated. However, the potential drawback is selection of multidrug-resistant (MDR) organisms. ADE is widely recommended in the management of antimicrobial therapy in intensive care unit (ICU) patients. The Surviving Sepsis Campaign guidelines describe and recommend the process for selecting antimicrobial therapy as commencement of antimicrobials within the first hour, antimicrobial therapy broad enough to cover all likely pathogens, and daily reassessment for potential ADE. To date, no randomized study assessing this strategy is available for this specific population of cancer critically ill patients. In a recent systematic review based on 13 observational studies and one randomized controlled trial, the authors conclude that the equipoise remains and a large randomized trial is required to assess the effect of the antibiotics de-escalation strategy on the bacterial ecosystem, on MDR carriage, and on patient outcomes.

Conditions

Critical Care; Cancer

Keywords

critical care; cancer; antimicrobial treatment; de-escalation; septic shock; sepsis

Outcome Measures

Primary Outcomes (1)

• Hospital mortality

  death from any cause during hospital stay

  From day of inclusion until day of ICU discharge, up to 3 months

Secondary Outcomes (44)

• Death

  From day of inclusion until ICU discharge, day 28 and day 90

• ICU length of stay

  From day of inclusion until ICU discharge (until day 90)

• Hospital length of stay

  From day of inclusion until ICU discharge (until day 90)

• Severe organ dysfunctions

  From day of inclusion until ICU discharge (until day 90)

• Respiratory dysfunction-free days at day 28

  from inclusion to day 28

Study Arms (2)

Antibiotic de-escalation

EXPERIMENTAL

* According to the results of the antibiogram of the suspected causative bacteria, the ''pivotal'' antibiotic (antipseudomonal betalactam) used for empirical treatment is switched to an antibiotic with a spectrum as narrow as possible according to the targeted pathogens, * Stop the companion antibiotic (aminoglycoside, fluoroquinolone, macrolide) between day 2 and day 3 of antibiotic treatment as much as possible, * Stop the empirical antibiotic directed against methicillin-resistant staphylococcus aureus (MRSA) or an enterococcus in the absence of these bacteria in the culture.

Other: Antibiotic de-escalation

Standard treatment without de-escalation

ACTIVE COMPARATOR

* The companion antibiotic is stopped between day 3 and day 5 of antibiotic treatment as much as possible and according to the local prescription, * Empirical antibiotics directed against MRSA or enterococcus were used according to local prescription and/or international guidelines, * The pivotal antibiotic of the empirical treatment is continued for the entire duration of the treatment, independently of microbiological results. For prolonged treatment, the physician has the choice of de-escalating after 8-15 days of treatment.

Other: Standard treatment

Interventions

Antibiotic de-escalation OTHER

All the therapeutic protocols made the object of a consensus between the different partners of the study. Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.

Antibiotic de-escalation

Standard treatment OTHER

Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.

Standard treatment without de-escalation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years,
• Onco-hematology patient admitted to intensive care for sepsis or septic shock according to the following criteria:
• Sepsis:
• A suspected infection
• And an acute increase of ≥ 2 SOFA points (a proxy for organ dysfunction)
• Septic shock:
• sepsis
• and vasopressor therapy needed to elevate MAP ≥65 mm Hg and lactate \>2 mmol/L despite adequate fluid resuscitation
• Patient treated with an empirical antibiotic treatment,
• Patient with at least one microbiological sample collected at least within the first 48 hours following the diagnosis of sepsis in ICU
• Patient with an identified infectious site according to the definitions,
• Patient with an identified bacteria microorganism after microbiological examination,
• Patient affiliated to the national French statutory healthcare insurance system or beneficiary of this regimen.

You may not qualify if:

• Patient colonized with a multi-drug resistant organisms preventing de-escalation antibiotic,
• Pregnant or breast-feeding woman,
• No affiliation to the national French statutory healthcare insurance system,
• Patients deprived of liberty or placed under the authority of a tutor,
• Inappropriate probabilistic antibiotic treatment,
• Expected mortality within 48 hours,
• Patient admitted to the ICU for end-of-life care (do-not-resuscitate patients) . Do-not-intubate (DNI) patients can be included.

Sponsors & Collaborators

• Institut Paoli-Calmettes: lead

Study Sites (1)

Institut Paoli Calmettes

Marseille, 13273, France

Location

Related Links

• Institut Paoli-Calmettes

MeSH Terms

Conditions

Neoplasms; Shock, Septic; Sepsis

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Shock

Study Officials

• MOKART Djamel, MD

  Institut Paoli-Calmettes

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2018
• First Posted: September 25, 2018
• Study Start: November 26, 2018
• Primary Completion: July 26, 2024
• Study Completion: July 26, 2024
• Last Updated: February 19, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)